Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis

NCT01038674 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Inflammation
Rheumatoid Arthritis

Interventions

DRUG: anti-IL-20
DRUG: placebo

Sponsor

Novo Nordisk A/S